FLUDROCORTISONE ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1955)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: V47IF0PVH4
Parent Compound: FLUDROCORTISONE

Structure
InChI Key SYWHXTATXSMDSB-GSLJADNHSA-N
Smile CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI
InChI=1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H31FO6
Molecular Weight 422.49
AlogP 2.44
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 100.9
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Mineralocorticoid receptor agonist PubMed Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 36

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Shock, Septic 3 D012772 ClinicalTrials
Adrenal Hyperplasia, Congenital 2 D000312 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Parkinson Disease 2 D010300 ClinicalTrials
Ovarian Hyperstimulation Syndrome 2 D016471 ClinicalTrials
Depressive Disorder 1 D003866 ClinicalTrials
Hearing Loss, Sensorineural 0 D006319 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.36
Nervous system disorders
9.76
Injury, poisoning and procedural complications
9.59
Cardiac disorders
9.42
Investigations
9.25
Vascular disorders
8.39
Metabolism and nutrition disorders
6.34
Gastrointestinal disorders
5.65
Psychiatric disorders
3.08
Respiratory, thoracic and mediastinal disorders
3.08
Immune system disorders
2.91
Musculoskeletal and connective tissue disorders
2.74
Renal and urinary disorders
2.74
Skin and subcutaneous tissue disorders
2.74
Product issues
2.4
Infections and infestations
2.23

Cross References

Resources Reference
ChEBI 5102
ChEMBL CHEMBL1201010
DrugCentral 1191
EPA CompTox DTXSID2023062
FDA SRS V47IF0PVH4
KEGG C08186
PubChem 225609
SureChEMBL SCHEMBL4737
ZINC ZINC000003977990
CONTENTS